Effect of doxercalciferol (1alpha-hydroxyvitamin D2) on PTH, bone turnover and bone mineral density in a hemodialysis patient with persistent secondary hyperparathyroidism post parathyroidectomy

Clin Nephrol. 2003 Jun;59(6):471-4. doi: 10.5414/cnp59471.

Abstract

The efficacy and safety of the vitamin D analog, doxercalciferol (1alpha-hydroxyvitamin D2, 1alphaD2) in the treatment of secondary hyperparathyroidism in hemodialysis patients has been previously reported. We report these effect of 16-week 1alphaD2 treatment on mineral metabolism and bone mineral density (BMD) in a hemodialysis patient with persistent secondary hyperparathyroidism post parathyroidectomy, resistant to previous calcitriol treatment. Levels of iPTH, bone-specific alkaline phosphatase and serum type I collagen C telopeptide were above normal at baseline and were substantially decreased with 1alphaD2 treatment (-92%, -63% and -53%, respectively). BMD increased in all areas: total skeleton (+6.5%), lumbar spine (+6.9%) and total femur (+4.3%). The patient showed no hypercalcemia, and phosphorus levels remained between 3.3 and 6.2 mg/dl.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Bone Density / drug effects*
  • Bone Remodeling / drug effects*
  • Ergocalciferols / therapeutic use*
  • Humans
  • Hyperparathyroidism, Secondary / drug therapy*
  • Male
  • Parathyroid Hormone / metabolism*
  • Parathyroidectomy
  • Renal Dialysis

Substances

  • Ergocalciferols
  • Parathyroid Hormone
  • 1 alpha-hydroxyergocalciferol